New drug cocktail aims to tame deadly transplant complication

NCT ID NCT07570745

Recruiting now Disease control Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

First seen May 06, 2026 · Last updated Jun 11, 2026 · Updated 5 times

Summary

This study tests whether adding a new oral drug (ivarmacitinib) to standard medicines can prevent a serious complication called graft-versus-host disease (GVHD) after a stem cell transplant from a female donor who has given birth. About 82 adults with blood cancers will receive the drug combo and be monitored for 6 months. The goal is to reduce severe GVHD while keeping the transplant working.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRAFT-VERSUS-HOST DISEASE (GVHD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Shanghai General Hospital Affiliated to Shanghai Jiao Tong University
RECRUITING

Shanghai, Shanghai Municipality, 210000, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BONE MARROW TRANSPLANTATION GRAFT-VERSUS-HOST DISEASE (GVHD)